| Literature DB >> 27350922 |
Emel Haciislamoglu1, Fatma Colak1, Emine Canyilmaz1, Ahmet Yasar Zengin2, Ahmet Hakan Yilmaz3, Adnan Yoney1, Zumrut Bahat1.
Abstract
The aim of this study was to identify a rational strategy for the selection of multi-beam IMRT in patients with right breast cancer through the comparison of dosimetric parameters of the planning target volume (PTV) and organs at risk (OARs) using five different radiotherapy modalities. This was a retrospective study using computed tomography scans from ten patients with early-stage right breast cancer who had been treated previously. Three dimensional conformal radiotherapy (3DCRT), forward-planned IMRT (for-IMRT), inverse-planned IMRT (inv-IMRT), helical tomotherapy (HT), and volumetric-modulated arc therapy (VMAT) were planned for each patient. The plans were compared according to dose-volume histogram analysis. The most significant impact of inverse-planned multi-beam modalities for right breast cancer was the reduction of Dmax, Dmean, V53.5 and prescribed dose volume (cc) outside of the PTV (breast) (OB-V50) of the PTV. HT decreased the ipsilateral OAR volumes receiving higher doses. In exchange, HT also increased the volumes receiving low doses, which is known to lead to an increased rate of radiation-induced secondary malignancies. The heart, LAD, and contralateral doses for 3DCRT and for-IMRT were significantly lower than those for inv-IMRT, HT, and VMAT. In addition, inv-IMRT demonstrated an increase in exposed volume of heart, LAD, ipsilateral lung, and contralateral lung compared with those parameters for HT or VMAT. Although it is known to reduce cardiac toxicity with breath hold technique in left sided breast cancer, similarly it is possible for 3DCRT and for-IMRT techniques in right sided breast cancer even in free breathing.Entities:
Keywords: Doses to the heart and LAD; Helical tomotherapy; Multi-beam inverse planning; Right breast cancer; Volumetric arc therapy
Year: 2016 PMID: 27350922 PMCID: PMC4899391 DOI: 10.1186/s40064-016-2314-2
Source DB: PubMed Journal: Springerplus ISSN: 2193-1801
Dose–volume constraints for target and organs at risk (OARs)
| Target or OAR | Goal or constraint dose (%) |
|---|---|
| Planning target volume (PTV) | 45 or 47.5 Gy |
| Heart | V20 < 10 % |
| V30 < 3 % | |
| LAD | Dmax < 15 Gy |
| Dmean < 5 Gy | |
| Ipsilateral lung | V20 < 20 % |
| V50 = 0 | |
| Contralateral lung | V5 < 20 % |
| V10 = 0 | |
| Contralateral breast | Dmean < 4 Gy |
| Dmax < 10 Gy |
Fig. 1Dose–volume histograms of the five modalities for a typical patient are shown for planning target volüme
Comparision of target coverage metrics for the PTV as a function of plan modality ( ± SD)
| Metric | 3DCRT | for-IMRT | inv-IMRT | HT | VMAT | p-value |
|---|---|---|---|---|---|---|
| Dmax (Gy) | 55.94 ± 1.34 | 55.01 ± 1.30 | 54.16 ± 0.54 | 53.85 ± 0.66 | 55.08 ± 0.72 | <0.001 |
| Dmean (Gy) | 51.86 ± 1.04 | 51.66 ± 1.00 | 51.18 ± 0.36 | 50.85 ± 0.22 | 51.35 ± 0.40 | 0.019 |
| V53.5 (%) | 20.56 ± 15.60 | 13.03 ± 12.80 | 1.85 ± 1.77 | 0.39 ± 0.59 | 10.15 ± 2.98 | <0.001 |
| IB-V50Gy (cc) | 765 ± 338 | 659 ± 423 | 696 ± 314 | 750 ± 376 | 717 ± 399 | 0.964 |
| OB-V50Gy (cc) | 379 ± 323 | 245 ± 239 | 103 ± 58 | 76 ± 51 | 57 ± 29 | <0.001 |
| CN | 0.58 ± 0.07 | 0.62 ± 0.08 | 0.75 ± 0.05 | 0.80 ± 0.05 | 0.73 ± 0.06 | <0.001 |
| HI | 0.13 ± 0.02 | 0.12 ± 0.07 | 0.09 ± 0.01 | 0.06 ± 0.01 | 0.17 ± 0.02 | <0.001 |
| MU | 231 ± 29 MU | 222 ± 14 MU | 1245 ± 146 MU | 9284 ± 354 MU | 300 ± 52 MU | <0.001 |
D max dose, D mean dose, V volume (%) receiving x dose (Gy) or higher, IB-V prescribed dose volume (cc) inside of the PTV, OB-V prescribed dose volume (cc) outside of the PTV, mean dose, SD standard deviation, CN conformation number, HI homogeneity index, MU monitor unit
Fig. 2Dose–volume histograms of the five modalities for a typical patient are shown for a heart, b left anterior descending artery (LAD), c ipsilateral lung, d contralateral lung, e contralateral breast, and f Body-PTV
Comparision of dosimetric metrics of OARs as a function of plan modality ( ± SD)
| Metric | 3DCRT | for-IMRT | inv-IMRT | HT | VMAT | p-value |
|---|---|---|---|---|---|---|
| Heart (RB) | ||||||
| Dmax (Gy) | 2.73 ± 0.56 | 2.73 ± 0.52 | 17.80 ± 5.46 | 15.65 ± 3.38 | 12.87 ± 2.15 | <0.001 |
| Dmean (Gy) | 0.95 ± 0.17 | 0.93 ± 0.15 | 5.10 ± 1.20 | 3.74 ± 0.92 | 4.99 ± 0.76 | <0.001 |
| V5 (%) | 0.0 ± 0.0 | 0.0 ± 0.0 | 39.50 ± 19.02 | 27.60 ± 15.16 | 38.00 ± 12.10 | <0.001 |
| V10 (%) | 0.0 ± 0.0 | 0.0 ± 0.0 | 7.00 ± 4.26 | 3.50 ± 3.42 | 3.90 ± 2.95 | <0.001 |
| LAD (RB) | ||||||
| Dmax (Gy) | 1.00 ± 0.13 | 1.01 ± 0.16 | 8.10 ± 3.42 | 6.54 ± 1.85 | 4.63 ± 0.83 | <0.001 |
| Dmean (Gy) | 0.85 ± 0.20 | 0.81 ± 0.10 | 5.05 ± 1.56 | 3.49 ± 1.20 | 3.71 ± 0.67 | <0.001 |
| Ipsilateral lung | ||||||
| Dmax (Gy) | 51.50 ± 1.82 | 50.56 ± 1.34 | 45.96 ± 2.52 | 43.13 ± 4.32 | 44.26 ± 3.15 | <0.001 |
| Dmean (Gy) | 7.66 ± 2.50 | 7.49 ± 2.44 | 12.18 ± 3.21 | 4.93 ± 1.45 | 11.71 ± 3.47 | <0.001 |
| V5 (%) | 19.80 ± 7.12 | 12.93 ± 4.70 | 79.92 ± 13.02 | 49.40 ± 15.51 | 76.38 ± 20.37 | <0.001 |
| V10 (%) | 15.21 ± 5.05 | 15.22 ± 5.22 | 44.26 ± 20.71 | 20.92 ± 6.58 | 40.30 ± 16.07 | <0.001 |
| V20 (%) | 12.99 ± 4.60 | 12.93 ± 4.70 | 15.64 ± 7.37 | 6.91 ± 2.03 | 14.69 ± 5.52 | 0.005 |
| Contralateral lung | ||||||
| Dmax (Gy) | 1.52 ± 0.38 | 1.58 ± 0.37 | 11.67 ± 3.30 | 11.49 ± 4.22 | 6.25 ± 1.30 | <0.001 |
| Dmean (Gy) | 0.35 ± 0.08 | 0.35 ± 0.08 | 3.69 ± 1.13 | 2.46 ± 0.96 | 2.50 ± 0.57 | <0.001 |
| V5 (%) | 0.0 ± 0.0 | 0.0 ± 0.0 | 25.75 ± 18.43 | 14.16 ± 11.82 | 2.46 ± 4.55 | <0.001 |
| V10 (%) | 0.0 ± 0.0 | 0.0 ± 0.0 | 1.73 ± 2.27 | 1.41 ± 2.43 | 0.0 ± 0.0 | 0.016 |
| Contralateral breast | ||||||
| Dmax (Gy) | 2.53 ± 0.91 | 2.66 ± 0.99 | 7.90 ± 2.76 | 9.68 ± 1.88 | 9.58 ± 2.99 | <0.001 |
| Dmean (Gy) | 0.54 ± 0.14 | 0.53 ± 0.14 | 2.69 ± 0.78 | 2.96 ± 0.57 | 2.19 ± 0.49 | <0.001 |
| V3 (%) | 0.16 ± 0.31 | 0.17 ± 0.36 | 27.87 ± 15.98 | 48.72 ± 15.42 | 17.80 ± 8.79 | <0.001 |
| V5 (%) | 0.0 ± 0.0 | 0.0 ± 0.0 | 6.25 ± 6.98 | 14.54 ± 7.06 | 3.84 ± 3.87 | <0.001 |
| Body-PTV | ||||||
| V3 (%) | 7.81 ± 3.35 | 7.86 ± 3.05 | 51.98 ± 11.50 | 39.30 ± 10.30 | 40.77 ± 9.68 | <0.001 |
| V5 (%) | 5.76 ± 2.38 | 5.73 ± 2.23 | 34.57 ± 9.10 | 27.19 ± 8.31 | 25.79 ± 7.98 | <0.001 |
| V10 (%) | 4.53 ± 1.96 | 4.52 ± 1.88 | 15.32 ± 4.46 | 13.86 ± 4.66 | 11.69 ± 4.11 | <0.001 |
| V20 (%) | 3.45 ± 1.62 | 3.41 ± 1.59 | 4.91 ± 1.68 | 5.95 ± 2.24 | 4.67 ± 1.91 | 0.016 |
| V30 (%) | 2.80 ± 1.43 | 2.77 ± 1.42 | 1.92 ± 0.88 | 2.39 ± 1.07 | 1.66 ± 0.85 | 0.124 |
D max dose, D mean dose, V volume (%) receiving x dose (Gy) or higher
Estimated p-values for compared treatment modalities for heart, LAD and contralateral breast
| Metric | A versus B | A versus C | A versus D | A versus E | B versus C | B versus D | B versus E | C versus D | C versus E | D versus E |
|---|---|---|---|---|---|---|---|---|---|---|
| Heart (RB) | ||||||||||
| Dmax | NS | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | NS | 0.007 | 0.013 |
| Dmean | NS | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.002 | NS | 0.007 |
| V5 (%) | NS | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | NS | NS | NS |
| V10 (%) | NS | <0.001 | NS | 0.030 | <0.001 | NS | 0.030 | NS | NS | NS |
| LAD (RB) | ||||||||||
| Dmax | NS | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | NS | 0.002 | 0.016 |
| Dmean | NS | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.022 | 0.026 | NS |
| CB (RB) | ||||||||||
| V3 (%) | NS | <0.001 | <0.001 | 0.006 | <0.001 | <0.001 | 0.006 | 0.001 | NS | <0.001 |
| V5 (%) | NS | NS | <0.001 | NS | NS | <0.001 | NS | 0.003 | NS | <0.001 |
A, three-dimensional conformal radiotherapy (3DCRT); B, forward-planned intensity-modulated radiotherapy (for-IMRT); C, inverse-planned intensity-modulated radiotherapy (inv-IMRT); D, helical tomotherapy (HT) and E, volumetric-modulated arc therapy (VMAT); RB, right breast, CB, contralateral breast and NS, no significant statistical differences